|
1
|
Ma K, Du W, Wang X, Yuan S, Cai X, Liu D,
Li J and Lu L: Multiple functions of B cells in the pathogenesis of
systemic lupus erythematosus. Int J Mol Sci.
20(6021)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Möckel T, Basta F, Weinmann-Menke J and
Schwarting A: B cell activating factor (BAFF): Structure,
functions, autoimmunity and clinical implications in Systemic Lupus
Erythematosus (SLE). Autoimmun Rev. 20(102736)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shi F, Xue R, Zhou X, Shen P, Wang S and
Yang Y: Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune
disease. Immunopharmacol Immunotoxicol. 43:666–673. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dhillon S: Telitacicept: First approval.
Drugs. 81:1671–1675. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pizzato M, Li M, Vignat J, Laversanne M,
Singh D, La Vecchia C and Vaccarella S: The epidemiological
landscape of thyroid cancer worldwide: GLOBOCAN estimates for
incidence and mortality rates in 2020. Lancet Diabetes Endocrinol.
10:264–272. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhang M, Wang Y, Wang Y, Bai Y and Gu D:
Association between systemic lupus erythematosus and cancer
morbidity and mortality: Findings from cohort studies. Front Oncol.
12(860794)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Song L, Wang Y, Zhang J, Song N, Xu X and
Lu Y: The risks of cancer development in systemic lupus
erythematosus (SLE) patients: A systematic review and
meta-analysis. Arthritis Res Ther. 20(270)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bernatsky S, Ramsey-Goldman R, Labrecque
J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB,
Gladman D, et al: Cancer risk in systemic lupus: an updated
international multi-centre cohort study. J Autoimmun. 42:130–135.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tessler FN, Middleton WD and Grant EG:
Thyroid imaging reporting and data system (TI-RADS): A user's
guide. Radiology. 287:29–36. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Antonelli A, Mosca M, Fallahi P, Neri R,
Ferrari SM, D'Ascanio A, Ghiri E, Carli L, Miccoli P and
Bombardieri S: Thyroid cancer in systemic lupus erythematosus: a
case-control study. J Clin Endocrinol Metab. 95:314–318.
2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Okosieme OE, Evans C, Moss L, Parkes AB,
Premawardhana LD and Lazarus JH: Thyroglobulin antibodies in serum
of patients with differentiated thyroid cancer: Relationship
between epitope specificities and thyroglobulin recovery. Clin
Chem. 51:729–734. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Inui A, Ogasawara H, Naito T, Sekigawa I,
Takasaki Y, Hayashida Y, Takamori K and Ogawa H: Estrogen receptor
expression by peripheral blood mononuclear cells of patients with
systemic lupus erythematosus. Clin Rheumatol. 26:1675–1678.
2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zeng Q, Chen G, Vlantis A, Tse G and van
Hasselt C: The contributions of oestrogen receptor isoforms to the
development of papillary and anaplastic thyroid carcinomas. J
Pathol. 214:425–433. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kansakar E, Chang YJ, Mehrabi M and Mittal
V: Expression of estrogen receptor, progesterone receptor, and
vascular endothelial growth factor-A in thyroid cancer. Am Surg.
75:785–789; discussion 789. 2009.PubMed/NCBI
|
|
16
|
Lahita RG: The role of sex hormones in
systemic lupus erythematosus. Curr Opin Rheumatol. 11:352–356.
1999.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cooper GS, Dooley MA, Treadwell EL, St
Clair EW, Parks CG and Gilkeson GS: Hormonal, environmental, and
infectious risk factors for developing systemic lupus
erythematosus. Arthritis Rheum. 41:1714–1724. 1998.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kiriakidou M and Ching CL: Systemic lupus
erythematosus. Ann Intern Med. 172:ITC81–ITC96. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fan Y, Gao D and Zhang Z: Telitacicept, a
novel humanized, recombinant TACI-Fc fusion protein, for the
treatment of systemic lupus erythematosus. Drugs Today (Barc).
58:23–32. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wu D, Li J, Xu D, Merrill JT, van
Vollenhoven RF, Liu Y, Hu J, Li Y, Li F, Huang C, et al:
Telitacicept in patients with active systemic lupus erythematosus:
Results of a phase 2b, randomised, double-blind, placebo-controlled
trial. Ann Rheum Dis. 83:475–487. 2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Navarra SV, Guzmán RM, Gallacher AE, Hall
S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, et al:
Efficacy and safety of belimumab in patients with active systemic
lupus erythematosus: A randomised, placebo-controlled, phase 3
trial. Lancet. 377:721–731. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cheng J, Peng Y, Wu Q, Wu Q, He J and Yuan
G: Efficacy and safety of telitacicept therapy in systemic lupus
erythematosus with hematological involvement. Clin Rheumatol.
43:2229–2236. 2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang L, Qian G, Zhang H, Li Q, Chen L,
Tang X and Zhao H: Efficacy of telitacicept in a systemic lupus
erythematosus patient with suboptimal response to Belimumab: A case
report. Lupus. 33:172–175. 2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fan Q, Ji H, Liu Y, Jia C, Zou L and Yang
H: Refractory lupus hepatitis successfully treated with
telitacicept who failed to belimumab: A case report and literature
review. Lupus. 33:414–419. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ma X, Fu X, Cui B and Lin H: Telitacicept
for recalcitrant cutaneous manifestations of systemic lupus
erythematosus: A case report and review of the literature. Tohoku J
Exp Med. 258:219–223. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li S, Deng S, Wen S, Peng S, Jiang N, Li
B, Chen B, Yuan Y, Wu Q, Tao Y, et al: Telitacicept treatment
refractory lupus nephritis: A case report. Case Rep Nephrol Dial.
14:42–47. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang X, Lin F and Chen H: Efficacy and
safety of telitacicept in patients with lupus nephritis: A
single-center, real-world retrospective study. Clin Exp Nephrol.
28:902–909. 2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen R, Fu R, Lin Z, Huang C and Huang W:
The efficacy and safety of telitacicept for the treatment of
systemic lupus erythematosus: A real life observational study.
Lupus. 32:94–100. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sarzi-Puttini P, Ceribelli A, Marotto D,
Batticciotto A and Atzeni F: Systemic rheumatic diseases: From
biological agents to small molecules. Autoimmun Rev. 18:583–592.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dreyer L, Cordtz RL, Hansen IMJ,
Kristensen LE, Hetland ML and Mellemkjaer L: Risk of second
malignant neoplasm and mortality in patients with rheumatoid
arthritis treated with biological DMARDs: A danish population-based
cohort study. Ann Rheum Dis. 77:510–514. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dixon WG, Watson KD, Lunt M, Mercer LK,
Hyrich KL and Symmons DP: British Society For Rheumatology
Biologics Register Control Centre Consortium; British Society for
Rheumatology Biologics Register. Influence of anti-tumor necrosis
factor therapy on cancer incidence in patients with rheumatoid
arthritis who have had a prior malignancy: Results from the British
society for rheumatology biologics register. Arthritis Care Res
(Hoboken). 62:755–763. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Strangfeld A, Hierse F, Rau R, Burmester
GR, Krummel-Lorenz B, Demary W, Listing J and Zink A: Risk of
incident or recurrent malignancies among patients with rheumatoid
arthritis exposed to biologic therapy in the German biologics
register RABBIT. Arthritis Res Ther. 12(R5)2010.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Mastorino L, Dapavo P, Avallone G, Merli
M, Cariti C, Rubatto M, Pala V, Quaglino P and Ribero S: Biologic
treatment for psoriasis in cancer patients: Should they still be
considered forbidden? J Dermatolog Treat. 33:2495–2502.
2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pellegrini C, Esposito M, Rossi E, Gisondi
P, Piaserico S, Dapavo P, Conti A, Gambardella A, Burlando M,
Narcisi A, et al: Secukinumab in patients with psoriasis and a
personal history of malignancy: A multicenter real-life
observational study. Dermatol Ther (Heidelb). 12:2613–2626.
2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Blauvelt A: Safety of secukinumab in the
treatment of psoriasis. Expert Opin Drug Saf. 15:1413–1420.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Frieder J, Kivelevitch D and Menter A:
Secukinumab: A review of the anti-IL-17A biologic for the treatment
of psoriasis. Ther Adv Chronic Dis. 9:5–21. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gupta A, Peyrin-Biroulet L and
Ananthakrishnan AN: Risk of cancer recurrence in patients with
immune-mediated diseases with use of immunosuppressive therapies:
An updated systematic review and meta-analysis. Clin Gastroenterol
Hepatol. 22:499–512.e6. 2024.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Siegel CA, Finlayson SR, Sands BE and
Tosteson AN: Adverse events do not outweigh benefits of combination
therapy for Crohn's disease in a decision analytic model. Clin
Gastroenterol Hepatol. 10:46–51. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Scott FI, Vajravelu RK, Bewtra M, Mamtani
R, Lee D, Goldberg DS and Lewis JD: The benefit-to-risk balance of
combining infliximab with azathioprine varies with age: A markov
model. Clin Gastroenterol Hepatol. 13:302–309.e11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Buchbinder R, Barber M, Heuzenroeder L,
Wluka AE, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G,
Miller MH, et al: Incidence of melanoma and other malignancies
among rheumatoid arthritis patients treated with methotrexate.
Arthritis Rheum. 59:794–799. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Allegretti JR, Barnes EL and Cameron A:
Are patients with inflammatory bowel disease on chronic
immunosuppressive therapy at increased risk of cervical high-grade
dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 21:1089–1097.
2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Bernheim O, Colombel JF, Ullman TA,
Laharie D, Beaugerie L and Itzkowitz SH: The management of
immunosuppression in patients with inflammatory bowel disease and
cancer. Gut. 62:1523–1528. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Shelton E, Laharie D, Scott FI, Mamtani R,
Lewis JD, Colombel JF and Ananthakrishnan AN: Cancer recurrence
following immune-suppressive therapies in patients with
immune-mediated diseases: A systematic review and meta-analysis.
Gastroenterology. 151:97–109.e4. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Karadaghy OA, Kallogjeri D and Piccirillo
JF: Development of a new clinical severity staging system for
patients with nonmetastatic papillary thyroid carcinoma. JAMA
Otolaryngol Head Neck Surg. 143:1173–1180. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Torregrossa L, Poma AM, Macerola E, Rago
T, Vignali P, Romani R, Proietti A, Di Stefano I, Scuotri G,
Ugolini C, et al: The Italian consensus for the classification and
reporting of thyroid cytology: Cytohistologic and molecular
correlations on 37,371 nodules from a single institution. Cancer
Cytopathol. 130:899–912. 2022.PubMed/NCBI View Article : Google Scholar
|
